RE:A better way forward It gets frustrating to see the lack of a formal explanation at times when the company needs to pivot on a pipleline product.
What is the significance of the functional drink disappearing from the pipeline timeline when it was ready for commercialization? Why does they appear to be just a carrot (juice) for us? Or is it back to the drawing board with another carrier? Have they exhausted all potential customers who would consider O-BG as a carrier for CoQ10 and now they must wait for pre-clinical results on Y-BG and sodium aliginates?
For those who think some of us are just penny flippers: there is no doubt there are some well seasoned investors here who believe that this company could achieve a market cap well in excess of $500M and are dumbfounded by the pace to achieve this.
The share price speaks volumes on the assessment and perception of the company by investors. After a year of "progress and opportunity to be realized" it's at the bottom of the trading range in the low 60's.